{"title":"胰高血糖素样肽-1 （GLP-1）激动剂治疗饮食失调的影响：系统回顾和荟萃分析","authors":"Hanieh Radkhah, Shiva Rahimipour Anaraki, Peyvand Parhizkar Roudsari, Razman Arabzadeh Bahri, Diar Zooravar, Sara Asgarian, Reza Hosseini Dolama, Ali Alirezaei, Razieh Khalooeifard","doi":"10.1007/s40519-025-01720-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating disorder (BED). This systematic review evaluates the therapeutic effects of GLP-1 agonists on BED, focusing on weight management and eating behaviors.</p><p><strong>Methods: </strong>A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library, along with manual searches, identified studies assessing GLP-1 agonists in BED patients up to November 8, 2024. Observational studies and clinical trials meeting inclusion criteria were analyzed.</p><p><strong>Results: </strong>Five studies (182 participants) were included. Patients receiving GLP-1 agonists experienced greater weight loss (- 3.81 kg; 95% CI - 5.14 to - 2.49; p < 0.01, I<sup>2</sup>: 59.88%) compared to controls. GLP-1 agonists significantly reduced BMI (- 1.48 kg/m<sup>2</sup>) and waist circumference (- 3.14 cm). Binge Eating Scale (BES) scores improved significantly (- 8.14 points; 95% CI - 13.13 to - 3.15; p < 0.01), though heterogeneity was noted.</p><p><strong>Conclusions: </strong>This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups.</p><p><strong>Level of evidence: </strong>Level I, randomized controlled trials.</p>","PeriodicalId":11391,"journal":{"name":"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity","volume":"30 1","pages":"10"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787217/pdf/","citationCount":"0","resultStr":"{\"title\":\"The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.\",\"authors\":\"Hanieh Radkhah, Shiva Rahimipour Anaraki, Peyvand Parhizkar Roudsari, Razman Arabzadeh Bahri, Diar Zooravar, Sara Asgarian, Reza Hosseini Dolama, Ali Alirezaei, Razieh Khalooeifard\",\"doi\":\"10.1007/s40519-025-01720-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating disorder (BED). This systematic review evaluates the therapeutic effects of GLP-1 agonists on BED, focusing on weight management and eating behaviors.</p><p><strong>Methods: </strong>A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library, along with manual searches, identified studies assessing GLP-1 agonists in BED patients up to November 8, 2024. Observational studies and clinical trials meeting inclusion criteria were analyzed.</p><p><strong>Results: </strong>Five studies (182 participants) were included. Patients receiving GLP-1 agonists experienced greater weight loss (- 3.81 kg; 95% CI - 5.14 to - 2.49; p < 0.01, I<sup>2</sup>: 59.88%) compared to controls. GLP-1 agonists significantly reduced BMI (- 1.48 kg/m<sup>2</sup>) and waist circumference (- 3.14 cm). Binge Eating Scale (BES) scores improved significantly (- 8.14 points; 95% CI - 13.13 to - 3.15; p < 0.01), though heterogeneity was noted.</p><p><strong>Conclusions: </strong>This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups.</p><p><strong>Level of evidence: </strong>Level I, randomized controlled trials.</p>\",\"PeriodicalId\":11391,\"journal\":{\"name\":\"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity\",\"volume\":\"30 1\",\"pages\":\"10\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11787217/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40519-025-01720-9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40519-025-01720-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
摘要
目的：胰高血糖素样肽-1 （GLP-1）受体激动剂已经显示出治疗饮食失调（EDs）的潜力。最近的研究强调了它们对病理生理途径的影响，表明了它们的治疗前景，特别是对暴饮暴食症（BED）。本系统综述评估GLP-1激动剂对BED的治疗效果，重点关注体重管理和饮食行为。方法：系统检索PubMed、Scopus、Web of Science和Cochrane Library，以及人工检索，确定了截至2024年11月8日评估BED患者GLP-1激动剂的研究。对符合纳入标准的观察性研究和临床试验进行分析。结果：纳入5项研究（182名受试者）。接受GLP-1激动剂治疗的患者体重减轻幅度更大(- 3.81 kg；95% CI - 5.14 ~ - 2.49；P 2: 59.88%)。GLP-1激动剂显著降低BMI （- 1.48 kg/m2）和腰围（- 3.14 cm）。暴食量表（BES）得分显著提高(- 8.14分；95% CI - 13.13 ~ - 3.15；结论：本综述强调了GLP-1激动剂在BED治疗中的潜在作用。然而，鉴于数据有限，特别是关于BED以外的ed和这些药物的长期影响，建议进一步进行全面的临床试验，以评估各种GLP-1激动剂对不同人口群体中不同ed的影响。证据等级：一级，随机对照试验。
The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.
Purpose: Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating disorder (BED). This systematic review evaluates the therapeutic effects of GLP-1 agonists on BED, focusing on weight management and eating behaviors.
Methods: A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library, along with manual searches, identified studies assessing GLP-1 agonists in BED patients up to November 8, 2024. Observational studies and clinical trials meeting inclusion criteria were analyzed.
Results: Five studies (182 participants) were included. Patients receiving GLP-1 agonists experienced greater weight loss (- 3.81 kg; 95% CI - 5.14 to - 2.49; p < 0.01, I2: 59.88%) compared to controls. GLP-1 agonists significantly reduced BMI (- 1.48 kg/m2) and waist circumference (- 3.14 cm). Binge Eating Scale (BES) scores improved significantly (- 8.14 points; 95% CI - 13.13 to - 3.15; p < 0.01), though heterogeneity was noted.
Conclusions: This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups.
Level of evidence: Level I, randomized controlled trials.
期刊介绍：
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity is a scientific journal whose main purpose is to create an international forum devoted to the several sectors of eating disorders and obesity and the significant relations between them. The journal publishes basic research, clinical and theoretical articles on eating disorders and weight-related problems: anorexia nervosa, bulimia nervosa, subthreshold eating disorders, obesity, atypical patterns of eating behaviour and body weight regulation in clinical and non-clinical populations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
